ArticleBMC microbiology2025
Reproducible generation of Nipah virus pseudovirions with uniform incorporation of F and G surface glycoproteins for high-throughput neutralization assays.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Nipah virus (NiV) is a pathogen to be handled in BSL-4 facilities. Multiple surrogate systems such as virus-like particles (VLPs) and pseudoviruses enable carrying out NiV neutralization assays and study of virus entry pathways in biosafety level-2 (BSL-2) facilities. These are dual protein expression and surface display systems comprising NiV structural glycoproteins F and G as the key components. During generation of NiV VLPs or pseudovirions, ensuring batch to batch uniformity is a major concern due to the lack of proportionate incorporation of these proteins in the producer cells as well as their consistent incorporation in the particles. We established HEK293 pseudovirion producer cells that stably co-incorporated NiV F and G proteins to address the issue. Fluorescence-activated cell sorting (FACS) analysis of clonally selected cells for high and uniform level F and G protein co-incorporation; and their further expansion were carried out to further refine the system. High titer vesicular stomatitis virus (VSV)-based pseudoviruses which showed consistent incorporation of both the glycoprotein were reproducibly generated from these producer cells. In functional assays, these Nipah pseudovirions (NiV) exhibited a dose-dependent neutralization by commercial anti-NiV F and G antibodies as well as by convalescent serum from Nipah recovered patients. A pseudovirus neutralization test (PVNT) with a secreted alkaline phosphatase (SEAP) as the reporter was established in the study. The assay supports high-throughput adaptability with a quick turn-around time. It will aid large-scale human and animal serosurveillance studies in Nipah endemic regions as well as screening of virus entry inhibitors and monoclonal antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.